Irvine, California Clinical Trials

A listing of Irvine, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease

pao2
pao2/fio2 ratio
chest imaging
FIO2
covid-19
Octapharma Research Site
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +4 other locations
A Study Evaluating JUV DERM VOLUMA XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old

The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma XC injectable gel in adult participants seeking correction of temple hollowing

Steve Yoelin M.D. Medical Associates, Inc.
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +14 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

cardiovascular disease
tirzepatide
dulaglutide
body mass index
Diabetes Associates Medical Group
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +650 other locations
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

florbetapir
flortaucipir
alzheimer's disease
positron emission tomography
mini-mental state examination
Irvine Clinical Research Center
 (0.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +85 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
hemophilia
fitusiran
haemophilia a
factor ix
Investigational Site Number 8400010
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

hemarthrosis
hemophilia
fitusiran
haemophilia a
antihemophilic factor
Investigational Site Number 8400016
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
hemophilia
fitusiran
haemophilia a
factor ix
Investigational Site Number 8400010
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
None

University of Southern California
 (7.6 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (7.5 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
BCI-FES Therapy for Stroke Rehabilitation

There are over 7 million stroke survivors in the US alone, with approximately 795,000 new cases annually. Despite the best available physiotherapy, 30-60% of stroke survivors remain affected by difficulty walking, with foot weakness often being the main cause. Given that post-stroke gait impairments remain poorly addressed, new methods that …

ischemic stroke
spasticity
electrical stimulation
stroke rehabilitation
stroke
University of California, Irvine - Sue & Bill Gross Stem Cell Research Center
 (2.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location